Table of Contents
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Immunohematology Overview 6
3 Products under Development 7
3.1 Immunohematology – Pipeline Products by Stage of Development 7
3.2 Immunohematology – Pipeline Products by Segment 8
3.3 Immunohematology – Pipeline Products by Territory 9
3.4 Immunohematology – Pipeline Products by Regulatory Path 10
3.5 Immunohematology – Pipeline Products by Estimated Approval Date 11
4 Immunohematology – Pipeline Products under Development by Companies 12
4.1 Immunohematology Companies – Pipeline Products by Stage of Development 12
4.2 Immunohematology – Pipeline Products by Stage of Development 13
5 Immunohematology Companies and Product Overview 14
5.1 AbSorber AB Company Overview 14
5.1.1 AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 14
5.2 Alba Bioscience Limited Company Overview 15
5.2.1 Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 15
5.3 Amity University Company Overview 17
5.3.1 Amity University Pipeline Products & Ongoing Clinical Trials Overview 17
5.4 Arizona State University Company Overview 18
5.4.1 Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 18
5.5 Biofortuna Ltd Company Overview 19
5.5.1 Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 19
5.6 Grifols SA Company Overview 24
5.6.1 Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 24
5.7 Ortho-Clinical Diagnostics Inc Company Overview 25
5.7.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 25
5.8 Quotient Ltd Company Overview 27
5.8.1 Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 27
5.9 Transfusion & Transplantation Technologies (Inactive) Company Overview 30
5.9.1 Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 30
6 Immunohematology- Recent Developments 35
6.1 Nov 04, 2019: Quotient reports second quarter fiscal 2020 financial results 35
6.2 Nov 01, 2019: Haemonetics reports 2nd quarter and 1st half fiscal 2020 results; raises fiscal 2020 adjusted operating margin and adjusted EPS guidance 37
6.3 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results 39
6.4 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results. 40
6.5 Oct 14, 2019: Biocare Medical appoints Nicolas Barthelemy as Executive Chairman 41
6.6 Sep 24, 2019: Theradiag announces improved results for H1 2019 41
6.7 Sep 12, 2019: Haemonetics Appoints Stewart W. Strong As President, Global Hospital 44
6.8 Sep 11, 2019: Bio-Rad files new lawsuit against 10X Genomics for Patent Infringement 45
6.9 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 45
6.10 Aug 06, 2019: Haemonetics reports 1st Quarter Fiscal 2020 results, updates Fiscal 2020 earnings guidance and launches operational excellence program 46
7 Appendix 98
7.1 Methodology 98
7.2 About GlobalData 101
7.3 Contact Us 101
7.4 Disclaimer 101
Table 1: Immunohematology - Pipeline Products by Stage of Development 8
Table 2: Immunohematology - Pipeline Products by Segment 9
Table 3: Immunohematology - Pipeline Products by Territory 10
Table 4: Immunohematology - Pipeline Products by Regulatory Path 11
Table 5: Immunohematology - Pipeline Products by Estimated Approval Date 12
Table 6: Immunohematology Companies - Pipeline Products by Stage of Development 13
Table 7: Immunohematology - Pipeline Products by Stage of Development 14
Table 8: AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 15
Table 9: ABO Diagnostic Test - Product Status 15
Table 10: ABO Diagnostic Test - Product Description 15
Table 11: Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 16
Table 12: ALBAcyte O Adult i Cell Reagent - Product Status 16
Table 13: ALBAcyte O Adult i Cell Reagent - Product Description 16
Table 14: ALBAcyte O RhD VI Reagent Cells - Product Status 16
Table 15: ALBAcyte O RhD VI Reagent Cells - Product Description 17
Table 16: Amity University Pipeline Products & Ongoing Clinical Trials Overview 18
Table 17: Blood Group Testing Kit - Product Status 18
Table 18: Blood Group Testing Kit - Product Description 18
Table 19: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 19
Table 20: Blood Screening Immunosignaturing - Product Status 19
Table 21: Blood Screening Immunosignaturing - Product Description 19
Table 22: Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 20
Table 23: HemoPlex Kell Genotyping Kit - Product Status 20
Table 24: HemoPlex Kell Genotyping Kit - Product Description 20
Table 25: HemoPlex Kidd & Duffy Genotyping Kit - Product Status 21
Table 26: HemoPlex Kidd & Duffy Genotyping Kit - Product Description 21
Table 27: HemoPlex MNS Genotyping Kit - Product Status 21
Table 28: HemoPlex MNS Genotyping Kit - Product Description 21
Table 29: HemoPlex Multi Blood Group Genotyping Kit - Product Status 22
Table 30: HemoPlex Multi Blood Group Genotyping Kit - Product Description 22
Table 31: HemoPlex RHCE Screening Kit - Product Status 22
Table 32: HemoPlex RHCE Screening Kit - Product Description 22
Table 33: HemoPlex RHCE Variant Genotyping Kit - Product Status 23
Table 34: HemoPlex RHCE Variant Genotyping Kit - Product Description 23
Table 35: HemoPlex RHD & CE Genotyping Kit - Product Status 23
Table 36: HemoPlex RHD & CE Genotyping Kit - Product Description 23
Table 37: HemoPlex RHD Variant Genotyping Kit - Product Status 24
Table 38: HemoPlex RHD Variant Genotyping Kit - Product Description 24
Table 39: ThromboPlex HPA Screening Kit - Product Status 24
Table 40: ThromboPlex HPA Screening Kit - Product Description 25
Table 41: Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 26
Table 42: IH Blood Genotyping (D) Kit - Product Status 26
Table 43: IH Blood Genotyping (D) Kit - Product Description 26
Table 44: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 27
Table 45: ORTHO AutoVue - Rare Sera Assay - Product Status 27
Table 46: ORTHO AutoVue - Rare Sera Assay - Product Description 27
Table 47: ORTHO BioVue - Rare Sera Assay - Product Status 28
Table 48: ORTHO BioVue - Rare Sera Assay - Product Description 28
Table 49: Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 29
Table 50: Eluate Kit - Product Status 29
Table 51: Eluate Kit - Product Description 29
Table 52: Expanded IH Microarray - Product Status 30
Table 53: Expanded IH Microarray - Product Description 30
Table 54: IH Microarray Patient - Product Status 30
Table 55: IH Microarray Patient - Product Description 30
Table 56: Polyagglutionation Kit - Product Status 31
Table 57: Polyagglutionation Kit - Product Description 31
Table 58: Sensitivity Kit Anti-S, K, e, C - Product Status 31
Table 59: Sensitivity Kit Anti-S, K, e, C - Product Description 31
Table 60: Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33
List of Figures
Figure 1: Immunohematology - Pipeline Products by Stage of Development 7
Figure 2: Immunohematology - Pipeline Products by Segment 8
Figure 3: Immunohematology - Pipeline Products by Territory 9
Figure 4: Immunohematology - Pipeline Products by Regulatory Path 10
Figure 5: Immunohematology - Pipeline Products by Estimated Approval Date 11
【免責事項】
https://www.marketreport.jp/reports-disclaimer